Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astex Pharmaceuticals is set to present its data on its first-in-class direct acting antiviral agents (DAA) used to treat Hepatitis C Virus (HCV).
Subscribe to our email newsletter
Astex has utilized its proprietary fragment-based drug discovery approach – Pyramid to target an unknown allosteric binding site on the full length HCV NS3 protease – helicase complex.
The company noticed that the agents acting at this site have a novel mode of action and a different resistance profile compared to NS3 protease inhibitors.
The data represent a new approach to develop targeted agents to treat HCV infection.
The company is choosing a clinical candidate with a view to filing an Investigational New Drug (IND) application next year.
The research program has been supported with £2 million funding from the Wellcome Trust Seeding Drug Discovery initiative, is wholly owned by Astex.